Emerging Pharma Leaders Tapped by Pharmaceutical Executive Magazine - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Emerging Pharma Leaders Tapped by Pharmaceutical Executive Magazine



Pharmaceutical Executive, a sister publication of Pharmaceutical Technology,  presented 15 winners in its annual Emerging Pharma Leaders competition in its July issue.

The 15 trendsetters reflect an industry that is changing from Big Pharma to what Pharmaceutical Executive characterizes as growing to be small.

For the first time, we include line executives from generic medicines and vaccines, two adjacent business units which under turbulent market conditions have emerged as key sources of product and process innovation, says Editor William Looney. Several of this year's winners have graduated to new roles that reflect the growing importance the 'c suite' places on knowledge retention, information services and the seeding of skills and talent throughout the organization.”

Other recipients hold positions that reflect the need for active, institutionalized collaboration between the RD and commercial product teams, at the earliest stage of the development cycle,:” Looney adds. And in a business where customer insight is still in short supply, we find more leaders are entering the industry with valuable outside exposure to the fickle affiliations of the retail trade.

The winners can be viewed on the Pharmaceutical Executive website.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here